Clinical Trial Update: Safety and Efficacy of NNC 0142-0000-0002 in Subjects With Moderately to Severely Active Crohn's Disease [Phase 2]

View source ↗

Summary

Phase 2 trial results evaluating the safety and efficacy of NNC 0142-0000-0002 in patients with moderately to severely active Crohn's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• NNC 0142-0000-0002

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Inflammation, Crohn's Disease | Phase 2 | Status: COMPLETED